Wegovy (semaglutide) is a medication that helps with weight loss by mimicking a hormone that regulates appetite. It is prescribed to individuals with obesity or those with weight-related health problems. In the UK, Wegovy has been approved for NHS use for patients who meet certain criteria, providing a non-surgical option for those seeking medical weight-loss assistance.

The prognosis for gastrointestinal (GI) cancer depends on the type and stage of cancer at diagnosis. Early-stage GI cancers, including stomach, colon, and esophageal cancers, have better survival rates when treated with surgery, chemotherapy, or radiation. Advanced-stage cancers are more difficult to treat and often require palliative care.

A non-surgical sleeve refers to procedures that mimic the effects of sleeve gastrectomy but without surgery. One such method is the Endoscopic Sleeve Gastroplasty (ESG), which reduces stomach size using sutures inserted through an endoscope. This approach is less invasive, has a faster recovery time, and is typically used for patients who do not qualify for surgical interventions.

Gastric RNY, or Roux-en-Y gastric bypass, remains one of the most effective surgical options for treating obesity. By reducing the size of the stomach and bypassing a portion of the intestines, patients experience a significant reduction in hunger and an inability to eat large meals. Gastric RNY can lead to rapid weight loss and improvement or resolution of obesity-related conditions such as type 2 diabetes, sleep apnea, and hypertension.